**Core Concept**
The question tests the ability to select an appropriate muscle relaxant in a patient with complex comorbidities, specifically liver failure. The underlying principle is that certain muscle relaxants are metabolized by the liver, whereas others undergo hydrolysis independent of liver function.

**Why the Correct Answer is Right**
Cisatracurium is a non-depolarizing muscle relaxant that undergoes Hofmann elimination, a chemical process that occurs independently of liver or kidney function. This makes it an ideal choice for patients with liver failure. Cisatracurium's unique elimination pathway ensures its efficacy and safety in patients with compromised liver function, such as this alcoholic patient with liver failure.

**Why Each Wrong Option is Incorrect**
**Option B:** Rocuronium is primarily metabolized by the liver and excreted in the bile. In a patient with liver failure, rocuronium's clearance may be impaired, leading to prolonged neuromuscular blockade.
**Option C:** Vecuronium is also metabolized by the liver and excreted in the bile. Like rocuronium, its clearance may be affected in patients with liver failure, making it a less ideal choice.
**Option D:** Rapacuronium was withdrawn from the market due to its association with bronchospasm and laryngospasm. It is not a suitable option for this patient regardless of their comorbidities.

**Clinical Pearl / High-Yield Fact**
When selecting a muscle relaxant for patients with liver or renal failure, it is essential to consider their metabolism and elimination pathways. Non-depolarizing muscle relaxants like cisatracurium that undergo chemical degradation are generally safer and more effective in these patients.

**✓ Correct Answer: A. Cisatracurium**